Cost-effectiveness of human papillomavirus vaccination for prevention of cervical cancer in Taiwan

BMC Health Services Research

Volumn 10, Issue , 2010, Pages

  Liu, Pang Hsiang ^a,b   Hu, Fu Chang ^a   Lee, Ping Ing ^a   Chow, Song Nan ^a   Huang, Chao Wan ^a   Wang, Jung Der ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; CHILD; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; HEALTH CARE COST; HUMAN; LIFE EXPECTANCY; MASS SCREENING; MORTALITY; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; TAIWAN; UTERINE CERVIX TUMOR; VAGINA SMEAR;

CHILD; COST-BENEFIT ANALYSIS; DIRECT SERVICE COSTS; FEMALE; HUMANS; LIFE EXPECTANCY; MARKOV CHAINS; MASS SCREENING; PAPILLOMAVIRUS VACCINES; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; TAIWAN; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 77149144791     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-10-11     Document Type: Article

References (64)

1. Pap Smear Screening Registry System Annual Report, 2007 Taipei: Bureau of Health Promotion, Department of Health, Taiwan 2008
2. Epidemiology of human papillomavirus infection and cervical cancer and future perspectives in Hong Kong, Singapore and Taiwan. SK Tay HY Ngan TY Chu AN Cheung EH Tay, Vaccine 2008 26 Suppl 12 60 70 10.1016/j.vaccine.2008.05.042 18945415
3. Cancer Incidence and Mortality Rates in Taiwan. Taiwan Cancer Registry, Department of Health (Taiwan), http://crs.cph.ntu.edu.tw/uploadimages/Leading- 10.pdf
4. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. JM Walboomers MV Jacobs MM Manos FX Bosch JA Kummer KV Shah PJ Snijders J Peto CJ Meijer N Munoz, J Pathol 1999 189 1 12 19 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F 10451482
5. Epidemiologic evidence and human papillomavirus infection as a necessary cause of cervical cancer. EL Franco TE Rohan LL Villa, J Natl Cancer Inst 1999 91 6 506 511 10.1093/jnci/91.6.506 10088620
6. Prevalence of cervical human papillomavirus in Taiwanese women. CJ Jeng Phdl ML Ko QD Ling J Shen HW Lin CR Tzeng CM Ho TY Chien SC Chen, Clin Invest Med 2005 28 5 261 266 16265998
7. High prevalence of genital human papillomavirus type 52 and 58 infection in women attending gynecologic practitioners in South Taiwan. H Lin YY Ma JS Moh YC Ou SY Shen CC ChangChien, Gynecol Oncol 2006 101 1 40 45 10.1016/j.ygyno.2005.09.028 16256180
8. Cervical cancer screening program integrating Pap smear and HPV DNA testing: a population-based study. A Chao KH Hsu CH Lai HJ Huang S Hsueh SR Lin SM Jung FY Chao SL Huang CC Huang,, et al. Int J Cancer 2008 122 12 2835 2841 10.1002/ijc.23441 18338752
9. Type-specific distribution of HPV along the full spectrum of cervical carcinogenesis in Taiwan: an indication of viral oncogenic potential. DC Ding HC Hsu RL Huang HC Lai CY Lin MH Yu TY Chu, Eur J Obstet Gynecol Reprod Biol 2008 140 2 245 251 10.1016/j.ejogrb.2008.03.014 18502563
10. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. J Paavonen D Jenkins FX Bosch P Naud J Salmeron CM Wheeler SN Chow DL Apter HC Kitchener X Castellsague,, et al. Lancet 2007 369 9580 2161 2170 10.1016/S0140-6736(07)60946-5 17602732
11. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. J Paavonen P Naud J Salmeron CM Wheeler SN Chow D Apter H Kitchener X Castellsague JC Teixeira SR Skinner,, et al. Lancet 2009 374 9686 301 314 10.1016/S0140-6736(09)61248-4 19586656
12. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. LL Villa RL Costa CA Petta RP Andrade KA Ault AR Giuliano CM Wheeler LA Koutsky C Malm M Lehtinen,, et al. Lancet Oncol 2005 6 5 271 278 10.1016/S1470-2045(05)70101-7 15863374
13. Cost-effectiveness of a potential vaccine for human papillomavirus. GD Sanders AV Taira, Emerg Infect Dis 2003 9 1 37 48 12533280
14. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. SJ Goldie M Kohli D Grima MC Weinstein TC Wright FX Bosch E Franco, J Natl Cancer Inst 2004 96 8 604 615 15100338
15. Evaluating human papillomavirus vaccination programs. AV Taira CP Neukermans GD Sanders, Emerg Infect Dis 2004 10 11 1915 1923 15550200
16. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. M Brisson N Van de Velde P De Wals MC Boily, Vaccine 2007 25 29 5399 5408 10.1016/j.vaccine.2007.04.086 17561316
17. Model for assessing human papillomavirus vaccination strategies. EH Elbasha EJ Dasbach RP Insinga, Emerg Infect Dis 2007 13 1 28 41 10.3201/eid1301.060438 17370513
18. Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation. RP Insinga EJ Dasbach EH Elbasha A Puig LM Reynales-Shigematsu, Vaccine 2007 26 1 128 139 10.1016/j.vaccine.2007.10.056 18055075
19. A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program. S Kulasingam L Connelly E Conway JS Hocking E Myers DG Regan D Roder J Ross G Wain, Sex Health 2007 4 3 165 175 10.1071/SH07043 17931529
20. Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France. C Bergeron N Largeron R McAllister P Mathevet V Remy, Int J Technol Assess Health Care 2008 24 1 10 19 10.1017/ S0266462307080026 18218164 (Pubitemid 351158538)
21. Cost-effectiveness of human papillomavirus vaccination in the United States. HW Chesson DU Ekwueme M Saraiya LE Markowitz, Emerg Infect Dis 2008 14 2 244 251 10.3201/eid1402.070499 18258117
22. Economic evaluation of human papillomavirus vaccination in the United Kingdom. M Jit YH Choi WJ Edmunds, BMJ 2008 337 769 10.1136/bmj.a769 18640957
23. Health and economic implications of HPV vaccination in the United States. JJ Kim SJ Goldie, N Engl J Med 2008 359 8 821 832 10.1056/NEJMsa0707052 18716299
24. Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness analysis. SL Kulasingam S Benard RV Barnabas N Largeron ER Myers, Cost Eff Resour Alloc 2008 6 4 10.1186/1478-7547-6-4 18279515
25. Cost-utility analysis of vaccination against HPV in Israel. GM Ginsberg M Fisher I Ben-Shahar J Bornstein, Vaccine 2007 25 37-38 6677 6691 10.1016/j.vaccine.2007.07.018 17706844
26. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands. IM de Kok M van Ballegooijen JD Habbema, J Natl Cancer Inst 2009 101 15 1083 1092 10.1093/jnci/djp183 19571256
27. Economic evaluations of massive HPV vaccination: within-study and between study variations in incremental cost per QALY gained. J Puig-Junoy BG Lopez-Valcarcel, Prev Med 2009 48 5 444 448 10.1016/j.ypmed.2009.02.011 19232368
28. The cost-effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan. EJ Dasbach RP Insinga YC Yang RF Pwu C Lac EH Elbasha, Asian Pac J Cancer Prev 2008 9 3 459 466 18990021
29. Comparison of detailed and succinct cohort modelling approaches in a multi-regional evaluation of cervical cancer vaccination. D Debicki N Ferko N Demarteau S Gallivan C Bauch A Anonychuk L Mantovani S Capri CY Chou B Standaert,, et al. Vaccine 2008 26 Suppl 5 16 28 10.1016/j.vaccine.2008.02.040 18992379
30. Markov models in medical decision making: a practical guide. FA Sonnenberg JR Beck, Med Decis Making 1993 13 4 322 338 10.1177/ 0272989X9301300409 8246705
31. Human papillomavirus testing in primary cervical screening. J Cuzick A Szarewski G Terry L Ho A Hanby P Maddox M Anderson G Kocjan ST Steele J Guillebaud, Lancet 1995 345 8964 1533 1536 10.1016/S0140-6736(95)91086-7 7791438
32. Meta-analysis of Pap test accuracy. MT Fahey L Irwig P Macaskill, Am J Epidemiol 1995 141 7 680 689 7702044
33. Prevalence, acquisition, and clearance of cervical human papillomavirus infection among women with normal cytology: Hawaii Human Papillomavirus Cohort Study. MT Goodman YB Shvetsov K McDuffie LR Wilkens X Zhu PJ Thompson L Ning J Killeen L Kamemoto BY Hernandez, Cancer Res 2008 68 21 8813 8824 10.1158/0008-5472.CAN-08-1380 18974124
34. The natural history of human papillomavirus infection and cervical intraepithelial neoplasia among young women in the Guanacaste cohort shortly after initiation of sexual life. AC Rodriguez R Burk R Herrero A Hildesheim C Bratti ME Sherman D Solomon D Guillen M Alfaro R Viscidi,, et al. Sex Transm Dis 2007 34 7 494 502 17237737
35. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. AB Moscicki S Shiboski J Broering K Powell L Clayton N Jay TM Darragh R Brescia S Kanowitz SB Miller,, et al. J Pediatr 1998 132 2 277 284 10.1016/S0022-3476(98)70445-7 9506641
36. Natural history of cervicovaginal papillomavirus infection in young women. GY Ho R Bierman L Beardsley CJ Chang RD Burk, N Engl J Med 1998 338 7 423 428 10.1056/NEJM199802123380703 9459645
37. Persistence of type-specific human papillomavirus infection among cytologically normal women. A Hildesheim MH Schiffman PE Gravitt AG Glass CE Greer T Zhang DR Scott BB Rush P Lawler ME Sherman,, et al. J Infect Dis 1994 169 2 235 240 8106758 (Pubitemid 24045578)
38. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. EL Franco LL Villa JP Sobrinho JM Prado MC Rousseau M Desy TE Rohan, J Infect Dis 1999 180 5 1415 1423 10.1086/315086 10515798
39. Efficacy and cost-effectiveness of nationwide cervical cancer screening in Taiwan. SL Koong AM Yen TH Chen, J Med Screen 2006 13 Suppl 1 44 47 17227642
40. KR Stratton JS Durch RS Lawrence Eds, Vaccines for the 21st Century: A Tool for Decisionmaking Washington: National Academy Press 2000
41. Costs of cervical cancer and precancerous lesions treatment in a publicly financed health care system. CH Tang RF Pwu IC Tsai HI Wang SL You CA Chen PA Scuffham CY Hsieh CY Chou SR Lin,, et al. Arch Gynecol Obstet 19730873
42. Human papillomavirus types 52 and 58 are prevalent in cervical cancer from Chinese women. KL Liaw AW Hsing MH Schiffman SL You T Zhang R Burk CJ Chen, Int J Cancer 1997 73 5 775 776 10.1002/(SICI)1097-0215(19971127)73:5<775:: AID-IJC27>3.0.CO;2-3 9398061
43. Making choices in health, WHO guide to cost-effectiveness analysis Geneva: World Health Organisation 2003
44. Cost-effectiveness analyses of human papillomavirus vaccination. AT Newall P Beutels JG Wood WJ Edmunds CR MacIntyre, Lancet Infect Dis 2007 7 4 289 296 10.1016/S1473-3099(07)70083-X 17376386
45. Economic evaluation of vaccination programs: the impact of herd-immunity. M Brisson WJ Edmunds, Med Decis Making 2003 23 1 76 82 10.1177/0272989X02239651 12583457
46. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. DM Harper EL Franco CM Wheeler AB Moscicki B Romanowski CM Roteli-Martins D Jenkins A Schuind SA Costa Clemens G Dubin, Lancet 2006 367 9518 1247 1255 10.1016/S0140-6736(06)68439-0 16631880
47. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. LL Villa RL Costa CA Petta RP Andrade J Paavonen OE Iversen SE Olsson J Hoye M Steinwall G Riis-Johannessen,, et al. Br J Cancer 2006 95 11 1459 1466 10.1038/sj.bjc.6603469 17117182
48. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007 356 19 1915 1927 10.1056/NEJMoa061741 17494925
49. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). LE Markowitz EF Dunne M Saraiya HW Lawson H Chesson ER Unger, MMWR Recomm Rep 2007 56 RR-2 1 24 17380109
50. Human papillomavirus and cervical neoplasia: a case-control study in Taiwan. KL Liaw AW Hsing CJ Chen MH Schiffman TY Zhang CY Hsieh CE Greer SL You TW Huang TC Wu,, et al. Int J Cancer 1995 62 5 565 571 10.1002/ijc.2910620513 7665227
51. Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions. KL Liaw AG Glass MM Manos CE Greer DR Scott M Sherman RD Burk RJ Kurman S Wacholder BB Rush,, et al. J Natl Cancer Inst 1999 91 11 954 960 10.1093/jnci/91.11.954 10359548
52. The distribution and differential risks of human papillomavirus genotypes in cervical preinvasive lesions: A Taiwan Cooperative Oncologic Group Study. CA Chen CY Liu HH Chou CY Chou CM Ho NF Twu YY Kan MH Chuang TY Chu CY Hsieh, Int J Gynecol Cancer 2006 16 5 1801 1808 10.1111/j.1525-1438.2006.00655.x 17009975
53. Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. R Herrero PE Castle M Schiffman MC Bratti A Hildesheim J Morales M Alfaro ME Sherman S Wacholder S Chen,, et al. J Infect Dis 2005 191 11 1796 1807 10.1086/428850 15871111 (Pubitemid 40705385)
54. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. ER Myers DC McCrory K Nanda L Bastian DB Matchar, Am J Epidemiol 2000 151 12 1158 1171 10905528
55. Natural history of cervical intraepithelial neoplasia: a critical review. AG Ostor, Int J Gynecol Pathol 1993 12 2 186 192 10.1097/00004347-199304000- 00018 8463044
56. Natural history of cervical squamous intraepithelial lesions: a meta-analysis. J Melnikow J Nuovo AR Willan BK Chan LP Howell, Obstet Gynecol 1998 92 4 Pt 2 727 735 10.1016/S0029-7844(98)00245-2 9764690
57. Natural history of dysplasia of the uterine cervix. P Holowaty AB Miller T Rohan T To, J Natl Cancer Inst 1999 91 3 252 258 10.1093/jnci/91.3.252 10037103
58. Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. NF Schlecht RW Platt E Duarte-Franco MC Costa JP Sobrinho JC Prado A Ferenczy TE Rohan LL Villa EL Franco, J Natl Cancer Inst 2003 95 17 1336 1343 12953088 (Pubitemid 37160867)
59. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. AB Moscicki N Hills S Shiboski K Powell N Jay E Hanson S Miller L Clayton S Farhat J Broering,, et al. JAMA 2001 285 23 2995 3002 10.1001/jama.285.23.2995 11410098
60. Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear. MA Nobbenhuis TJ Helmerhorst AJ van den Brule L Rozendaal FJ Voorhorst PD Bezemer RH Verheijen CJ Meijer, Lancet 2001 358 9295 1782 1783 10.1016/S0140-6736(01)06809-X 11734239
61. The screening histories of women with invasive cervical cancer, Connecticut. DT Janerich O Hadjimichael PE Schwartz DM Lowell JW Meigs MJ Merino JT Flannery AP Polednak, Am J Public Health 1995 85 6 791 794 10.2105/AJPH.85.6.791 7762711
62. Rapidly progressive cervical cancer: the Connecticut experience. PE Schwartz O Hadjimichael DM Lowell MJ Merino D Janerich, Am J Obstet Gynecol 1996 175 4 Pt 2 1105 1109 10.1016/S0002-9378(96)70012-1 8885794
63. Outpatient excisional management of cervical intraepithelial neoplasia. A prospective, randomized comparison between loop diathermy excision and laser excisional conization. OA Oyesanya CN Amerasinghe EA Manning, Am J Obstet Gynecol 1993 168 2 485 488 8438914
64. Cervical intraepithelial neoplasia in women infected with the human immunodeficiency virus: outcome after loop electrosurgical excision. TC Wright Jr J Koulos F Schnoll J Swanbeck TV Ellerbrock MA Chiasson RM Richart, Gynecol Oncol 1994 55 2 253 258 10.1006/gyno.1994.1286 7959293